STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.82
+2.69%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$24.49
From 52W high−35.28%
Volume694712.00
Market cap$1.60B
P/E (TTM)—
P/S (TTM)58.1x
Div yield—
Key dataOct 19, 2026
Open
$24.49
From 52W high
−35.28%
Volume
694712.00
Market cap
$1.60B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.3x
P/E (TTM)
—
RSI (14)
42.0
MomentumView details →
1D Return
+2.69%
YTD Return
−22.94%
SummaryUpdated Jun 1, 2026
Stoke Therapeutics, Inc. (NASDAQ:STOK) is an early-stage biopharmaceutical company founded in 2014 and headquartered in Bedford, Massachusetts. Originally incorporated as ASOthera Pharmaceuticals, Inc., the company changed its name to Stoke Therapeutics in May 2016 and went public in June 2019. Stoke focuses on developing novel antisense oligonucleotide medicines to treat severe genetic diseases by addressing their underlying molecular causes rather than just managing symptoms.
Similar companies
Latest newsMore news →
Stoke Therapeutics completed a successful meeting with the U.S. FDA to align on key aspects of a planned U.S. New Drug Application for zorevunersen, its investigational treatment for Dravet syndrome.15d agoAlexander (Bo) Cumbo was appointed as a Class III director of Stoke Therapeutics, effective September 23, 2026.24d agoEdward M. Kaye, M.D. resigned as a Class III director of Stoke Therapeutics, effective September 23, 2026.24d ago